172 related articles for article (PubMed ID: 27447851)
1. Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.
Moltó J; Estévez JA; Miranda C; Cedeño S; Clotet B; Valle M
Br J Clin Pharmacol; 2016 Dec; 82(6):1528-1538. PubMed ID: 27447851
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
Schipani A; Dickinson L; Boffito M; Austin R; Owen A; Back D; Khoo S; Davies G
J Acquir Immune Defic Syndr; 2013 Jan; 62(1):60-6. PubMed ID: 23011396
[TBL] [Abstract][Full Text] [Related]
3. Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling.
Montanha MC; Fabrega F; Howarth A; Cottura N; Kinvig H; Bunglawala F; Lloyd A; Denti P; Waitt C; Siccardi M
Clin Pharmacokinet; 2022 Mar; 61(3):375-386. PubMed ID: 34635995
[TBL] [Abstract][Full Text] [Related]
4. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
[TBL] [Abstract][Full Text] [Related]
5. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.
Song I; Borland J; Chen S; Lou Y; Peppercorn A; Wajima T; Min S; Piscitelli SC
Br J Clin Pharmacol; 2011 Jul; 72(1):103-8. PubMed ID: 21342217
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
Sevinsky H; Zaru L; Wang R; Xu X; Pikora C; Correll TA; Eley T
Pediatr Infect Dis J; 2018 Jun; 37(6):e157-e165. PubMed ID: 29206748
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
von Hentig N; Müller A; Rottmann C; Wolf T; Lutz T; Klauke S; Kurowski M; Oertel B; Dauer B; Harder S; Staszewski S
Antimicrob Agents Chemother; 2007 Apr; 51(4):1431-9. PubMed ID: 17296738
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients.
Punyawudho B; Thammajaruk N; Ruxrungtham K; Avihingsanon A
Int J Antimicrob Agents; 2017 Mar; 49(3):327-332. PubMed ID: 28109702
[TBL] [Abstract][Full Text] [Related]
9. Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.
Hong Y; Kowalski KG; Zhang J; Zhu L; Horga M; Bertz R; Pfister M; Roy A
Antimicrob Agents Chemother; 2011 Dec; 55(12):5746-52. PubMed ID: 21930880
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
Zhu L; Hruska M; Hwang C; Shah V; Furlong M; Hanna GJ; Bertz R; Landry IS
Antimicrob Agents Chemother; 2015 Jul; 59(7):3816-22. PubMed ID: 25870057
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients.
Singkham N; Avihingsanon A; Brundage RC; Birnbaum AK; Thammajaruk N; Ruxrungtham K; Bunupuradah T; Kiertiburanakul S; Chetchotisakd P; Punyawudho B;
Expert Rev Clin Pharmacol; 2022 Jan; 15(1):99-108. PubMed ID: 34727835
[TBL] [Abstract][Full Text] [Related]
12. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations.
Smith DE; Jeganathan S; Ray J
HIV Clin Trials; 2006; 7(1):34-8. PubMed ID: 16632461
[TBL] [Abstract][Full Text] [Related]
13. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
Conradie F; Zorrilla C; Josipovic D; Botes M; Osiyemi O; Vandeloise E; Eley T; Child M; Bertz R; Hu W; Wirtz V; McGrath D
HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187
[TBL] [Abstract][Full Text] [Related]
14. Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients.
Gervasoni C; Riva A; Rizzardini G; Clementi E; Galli M; Cattaneo D
Antivir Ther; 2015; 20(4):449-51. PubMed ID: 25279606
[TBL] [Abstract][Full Text] [Related]
15. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
[TBL] [Abstract][Full Text] [Related]
16. Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?
Gervasoni C; Meraviglia P; Minisci D; Ferraris L; Riva A; Landonio S; Cozzi V; Charbe N; Molinari L; Rizzardini G; Clementi E; Galli M; Cattaneo D
PLoS One; 2015; 10(4):e0123670. PubMed ID: 25875091
[TBL] [Abstract][Full Text] [Related]
17. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
[TBL] [Abstract][Full Text] [Related]
18. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
Veldkamp AI; van Heeswijk RP; Mulder JW; Meenhorst PL; Schreij G; van der Geest S; Lange JM; Beijnen JH; Hoetelmans RM
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):344-9. PubMed ID: 11468422
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults.
Hiransuthikul A; Thammajaruk N; Techatanawat I; Karachot B; Chuasuwan B; Manamuti C; Duereh M; Sawpitiporn M; Sophonphan J; Gatechompol S; Avihingsanon A; Bowonwattanuwong C; Ruxrungtham K;
Antivir Ther; 2018; 23(8):699-703. PubMed ID: 30265243
[TBL] [Abstract][Full Text] [Related]
20. Influence of
Singkham N; Avihingsanon A; Thammajaruk N; Ruxrungtham K; Bunupuradah T; Kiertiburanakul S; Chetchotisakd P; Burger DM; Emery S; Punyawudho B
Pharmacogenomics; 2019 May; 20(7):517-527. PubMed ID: 31124411
[No Abstract] [Full Text] [Related]
[Next] [New Search]
